GGrantIndex
Sort

51,593 grants matching hepatitis

Testing an mHealth System for Integrating Alcohol Use Treatment with Hepatology Care for Patients with Alcohol-associated Liver Disease

$630,575
Andrew Quanbeck · University Of Wisconsin-Madison · R01 · FY2023 · AA

Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy

$630,556
Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2013 · DK

Development of simpler immunotheraputics

$630,497
Arya Biragyn · National Institute On Aging · ZIA · FY2021 · AG

Pathogenesis of HIV and HCV in Hemophilia: HGDS

$630,488
Children'S Hospital Los Angeles · R01 · FY2003 · HD

Social Media Mining for Pharmacovigilance

$630,471
Graciela Gonzalez Hernandez · University Of Pennsylvania · R01 · FY2019 · LM

Biological Mechanisms through which TMAO Promotes Atherosclerosis

$630,470
Hooman Allayee · University Of Southern California · R01 · FY2020 · HL

Multidisciplinary Studies of Hematopoietic Malignancies

$630,447
Lindsay Morton · Division Of Cancer Epidemiology And Genetics · ZIA · FY2017 · CA

Creation of in vivo active chemical probes for CAMKK2 to treat cancer

$630,383
David Harold Drewry · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA

Bio-digital Rapid Alert to Identify Neuromorbidity

$630,376
Robert S. Clark · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · NS

Community-based interventions to reduce mortality from neonatal infection

$630,365
Waldemar A. Carlo · University Of Alabama At Birmingham · U01 · FY2012 · HD

IDENTIFICATION AND PRECLINICAL EVALUATION OF NOVEL THERAPEUTIC APPROACHES TO DYSKERATOSIS CONGENITA

$630,241
Frederick Bradley Johnson · University Of Pennsylvania · R01 · FY2021 · HL

Development of Natural Product Leads as Anticancer Therapeutics

$630,232
John Beutler · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

CSDE1 as a Post Transcriptional Regulator of the LDLR

$630,223
John S Chorba · University Of California, San Francisco · R01 · FY2023 · HL

Search For New and Emerging Etiologic Agents

$630,214
Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

Drug target validation of the enterovirus D68 2A protease

$630,155
Jun Wang · Rutgers Biomedical And Health Sciences · R01 · FY2024 · AI

Developmental pathways, environmental agents, and epigenetics in liver disease

$630,122
Keith D Robertson · Augusta University · R01 · FY2011 · AA

Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapy

$630,041
Andre Michael Lieber · University Of Washington · R01 · FY2019 · HL

Injection Risk Networks in Rural Puerto Rico

$630,001
Kirk Dombrowski · University Of Nebraska Lincoln · R01 · FY2015 · DA

IMPROVED BARRIER HOUSING FOR BIOMEDICAL RESEARCH BLDG

$630,000
University Of Pennsylvania · G20 · FY2004 · RR

TESTING THE SAFETY AND EFFICACY OF CARG-201, AN RNA REPLICON-BASED THERAPEUTIC VACCINE FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS

$629,992
Carogen Corp · · FY2024 · Defense Health Agency

Estrogen Regulation of Hepatic Growth

$629,907
Wolfram Goessling · Brigham And Women'S Hospital · R01 · FY2018 · DK

Estrogen Regulation of Hepatic Growth

$629,907
Wolfram Goessling · Brigham And Women'S Hospital · R01 · FY2020 · DK

Estrogen Regulation of Hepatic Growth

$629,907
Wolfram Goessling · Brigham And Women'S Hospital · R01 · FY2019 · DK

Estrogen Regulation of Hepatic Growth

$629,907
Wolfram Goessling · Brigham And Women'S Hospital · R01 · FY2017 · DK

Role of Retinoid X Receptor Alpha in regulating PCSK9 transcription in the liver

$629,891
Qing Miao · Nyu Long Island School Of Medicine · R01 · FY2023 · DK